Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 6 | 2022 | 128 | 1.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2012 | 236 | 1.010 |
Why?
|
| Carcinogenesis | 2 | 2022 | 20 | 0.910 |
Why?
|
| Adenoma | 2 | 2022 | 61 | 0.870 |
Why?
|
| Lung Neoplasms | 6 | 2012 | 543 | 0.860 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 61 | 0.840 |
Why?
|
| DNA Damage | 1 | 2021 | 26 | 0.730 |
Why?
|
| MicroRNAs | 1 | 2022 | 37 | 0.730 |
Why?
|
| Glioblastoma | 1 | 2021 | 13 | 0.730 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 56 | 0.730 |
Why?
|
| Carcinoma | 1 | 2022 | 68 | 0.720 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2021 | 13 | 0.680 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 91 | 0.680 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2021 | 29 | 0.660 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 135 | 0.500 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 101 | 0.460 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 109 | 0.420 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.400 |
Why?
|
| Quinazolines | 3 | 2012 | 17 | 0.380 |
Why?
|
| Germ-Line Mutation | 3 | 2021 | 14 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 164 | 0.360 |
Why?
|
| Aged | 15 | 2021 | 7572 | 0.340 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2020 | 36 | 0.330 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 7 | 0.330 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 10 | 0.330 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 15 | 0.330 |
Why?
|
| Female | 17 | 2021 | 13239 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2007 | 54 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 26 | 0.330 |
Why?
|
| Humans | 22 | 2022 | 23541 | 0.320 |
Why?
|
| Long Interspersed Nucleotide Elements | 2 | 2021 | 5 | 0.310 |
Why?
|
| Middle Aged | 12 | 2021 | 8134 | 0.310 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 26 | 0.300 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 78 | 0.290 |
Why?
|
| Adult | 9 | 2021 | 7168 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 2 | 0.270 |
Why?
|
| Age Factors | 2 | 2021 | 648 | 0.240 |
Why?
|
| Male | 12 | 2021 | 12743 | 0.240 |
Why?
|
| Biomarkers, Tumor | 5 | 2020 | 201 | 0.230 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 401 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2016 | 46 | 0.230 |
Why?
|
| DNA Mutational Analysis | 3 | 2020 | 51 | 0.210 |
Why?
|
| DNA Repair Enzymes | 2 | 2016 | 8 | 0.210 |
Why?
|
| GTP Phosphohydrolases | 2 | 2020 | 6 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 48 | 0.210 |
Why?
|
| Genes, BRCA1 | 2 | 2020 | 12 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 19 | 0.200 |
Why?
|
| Membrane Proteins | 2 | 2020 | 151 | 0.190 |
Why?
|
| Genes, p53 | 2 | 2020 | 18 | 0.190 |
Why?
|
| Prognosis | 3 | 2018 | 749 | 0.180 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 7 | 0.180 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 10 | 0.170 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 5 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.170 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 155 | 0.170 |
Why?
|
| Survival Rate | 2 | 2012 | 323 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 358 | 0.160 |
Why?
|
| Phthalazines | 1 | 2020 | 6 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 5 | 0.160 |
Why?
|
| Piperazines | 1 | 2020 | 82 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 231 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 203 | 0.150 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 8 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2018 | 43 | 0.150 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 44 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 3 | 0.140 |
Why?
|
| Chimerism | 1 | 2018 | 5 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 5 | 0.140 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 5 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 6 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 198 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2018 | 30 | 0.140 |
Why?
|
| X-linked Nuclear Protein | 1 | 2017 | 2 | 0.140 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2017 | 3 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 4 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 91 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 40 | 0.130 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 3 | 0.130 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 6 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 4 | 0.130 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 10 | 0.130 |
Why?
|
| Mutation | 5 | 2018 | 330 | 0.120 |
Why?
|
| Young Adult | 1 | 2021 | 1745 | 0.120 |
Why?
|
| ErbB Receptors | 4 | 2012 | 54 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 3767 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 74 | 0.120 |
Why?
|
| CpG Islands | 2 | 2017 | 43 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 168 | 0.110 |
Why?
|
| Brain | 1 | 2021 | 1215 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 505 | 0.110 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2012 | 3093 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 25 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 84 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2013 | 15 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 27 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 340 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 85 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2012 | 76 | 0.090 |
Why?
|
| Illinois | 1 | 2012 | 222 | 0.090 |
Why?
|
| Disease Progression | 2 | 2018 | 530 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1492 | 0.090 |
Why?
|
| Meiosis | 1 | 2010 | 1 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2010 | 13 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 11 | 0.090 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2010 | 20 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2010 | 33 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 97 | 0.080 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 31 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 30 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 49 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 51 | 0.080 |
Why?
|
| Lung | 1 | 2010 | 153 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 34 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 20 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2007 | 2 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 114 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2007 | 245 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 114 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 240 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3122 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 276 | 0.060 |
Why?
|
| Patient Selection | 1 | 2007 | 170 | 0.060 |
Why?
|
| Logistic Models | 1 | 2007 | 357 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 379 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 261 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2021 | 19 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 84 | 0.040 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 10 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 71 | 0.040 |
Why?
|
| Standard of Care | 1 | 2020 | 11 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 316 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 443 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2018 | 3 | 0.040 |
Why?
|
| Galectins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 13 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 20 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 24 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 127 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 453 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 209 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 48 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 555 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 53 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 260 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 17 | 0.020 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 60 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 114 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 401 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 4 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 6 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 11 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 49 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 44 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 172 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 17 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 59 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 196 | 0.020 |
Why?
|